JP2023037000A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023037000A5 JP2023037000A5 JP2023003355A JP2023003355A JP2023037000A5 JP 2023037000 A5 JP2023037000 A5 JP 2023037000A5 JP 2023003355 A JP2023003355 A JP 2023003355A JP 2023003355 A JP2023003355 A JP 2023003355A JP 2023037000 A5 JP2023037000 A5 JP 2023037000A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- antibody
- cdr1
- acid sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023003355A JP2023037000A (ja) | 2018-07-20 | 2023-01-12 | 抗ｃｄ４０抗体及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2018/096494 WO2020014974A1 (en) | 2018-07-20 | 2018-07-20 | Anti-cd40 antibodies and uses thereof |
| JP2021504146A JP7212138B2 (ja) | 2018-07-20 | 2018-07-20 | 抗ｃｄ４０抗体及びその使用 |
| JP2023003355A JP2023037000A (ja) | 2018-07-20 | 2023-01-12 | 抗ｃｄ４０抗体及びその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021504146A Division JP7212138B2 (ja) | 2018-07-20 | 2018-07-20 | 抗ｃｄ４０抗体及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023037000A JP2023037000A (ja) | 2023-03-14 |
| JP2023037000A5 true JP2023037000A5 (https=) | 2023-12-12 |
Family
ID=69164892
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021504146A Active JP7212138B2 (ja) | 2018-07-20 | 2018-07-20 | 抗ｃｄ４０抗体及びその使用 |
| JP2023003355A Pending JP2023037000A (ja) | 2018-07-20 | 2023-01-12 | 抗ｃｄ４０抗体及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021504146A Active JP7212138B2 (ja) | 2018-07-20 | 2018-07-20 | 抗ｃｄ４０抗体及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11142582B2 (https=) |
| EP (1) | EP3823987A4 (https=) |
| JP (2) | JP7212138B2 (https=) |
| KR (1) | KR102728939B1 (https=) |
| CN (1) | CN112566933B (https=) |
| AU (1) | AU2018432434B2 (https=) |
| BR (1) | BR112021001083A2 (https=) |
| CA (1) | CA3105875A1 (https=) |
| IL (1) | IL280281B2 (https=) |
| MX (2) | MX2021000688A (https=) |
| SG (1) | SG11202100510PA (https=) |
| WO (1) | WO2020014974A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3823987A4 (en) * | 2018-07-20 | 2022-03-02 | Eucure (Beijing) Biopharma Co., Ltd | ANTI-CD40 ANTIBODIES AND USES THEREOF |
| EP4229096A4 (en) * | 2020-10-14 | 2024-06-12 | Eucure (Beijing) Biopharma Co., Ltd | ANTI-PD-1/CD40 BISPECIFIC ANTIBODIES AND USES THEREOF |
| WO2023198194A1 (en) * | 2022-04-15 | 2023-10-19 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-cd40 antibodies and uses thereof |
| AU2023281615A1 (en) * | 2022-06-01 | 2024-12-05 | Syncromune, Inc. | A method for the treatment of cancer via tumor cell lysis and intratumoral administration of combinations of immunotherapeutic ingredients |
| CN116023495B (zh) * | 2022-09-05 | 2023-10-03 | 上海百英生物科技股份有限公司 | 一种抗cd40纳米抗体及其制备方法与应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| WO1989001973A2 (en) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| AU648261B2 (en) | 1989-08-18 | 1994-04-21 | Novartis Vaccines And Diagnostics, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6051228A (en) * | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| MX2008013993A (es) | 2006-05-03 | 2009-05-11 | Univ Colorado | Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular. |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| AU2010222942B2 (en) * | 2009-03-10 | 2013-01-10 | Baylor Research Institute | Anti-CD40 antibodies and uses thereof |
| MA34010B1 (fr) | 2010-02-04 | 2013-02-01 | Hoffmann La Roche | Anticorps monoclonal anti-cd44 destiné à être utilisé pour traiter le carcinome à cellules squameuses de la tête et du cou |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| ES2709654T3 (es) * | 2011-04-29 | 2019-04-17 | Apexigen Inc | Anticuerpos anti-CD40 y métodos de uso |
| KR102270618B1 (ko) | 2012-10-30 | 2021-06-30 | 아펙시젠, 인코포레이티드 | 항-cd40 항체 및 사용 방법 |
| BR112017027549A2 (pt) * | 2015-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | anticorpo para cd40 |
| BR112018004296B1 (pt) * | 2015-09-04 | 2020-05-05 | Primatope Therapeutics Inc | anticorpos anti-cd40 humanizados e usos dos mesmos |
| US12297266B2 (en) | 2016-04-18 | 2025-05-13 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human CD40 and uses thereof |
| WO2018233607A1 (en) | 2017-06-19 | 2018-12-27 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric cd40 |
| EP3823987A4 (en) * | 2018-07-20 | 2022-03-02 | Eucure (Beijing) Biopharma Co., Ltd | ANTI-CD40 ANTIBODIES AND USES THEREOF |
-
2018
- 2018-07-20 EP EP18927035.8A patent/EP3823987A4/en active Pending
- 2018-07-20 CN CN201880095772.4A patent/CN112566933B/zh active Active
- 2018-07-20 KR KR1020217004891A patent/KR102728939B1/ko active Active
- 2018-07-20 JP JP2021504146A patent/JP7212138B2/ja active Active
- 2018-07-20 WO PCT/CN2018/096494 patent/WO2020014974A1/en not_active Ceased
- 2018-07-20 CA CA3105875A patent/CA3105875A1/en active Pending
- 2018-07-20 IL IL280281A patent/IL280281B2/en unknown
- 2018-07-20 MX MX2021000688A patent/MX2021000688A/es unknown
- 2018-07-20 AU AU2018432434A patent/AU2018432434B2/en active Active
- 2018-07-20 BR BR112021001083-1A patent/BR112021001083A2/pt unknown
- 2018-07-20 SG SG11202100510PA patent/SG11202100510PA/en unknown
-
2021
- 2021-01-14 US US17/149,209 patent/US11142582B2/en active Active
- 2021-01-18 MX MX2025000992A patent/MX2025000992A/es unknown
- 2021-09-08 US US17/469,488 patent/US12134653B2/en active Active
-
2023
- 2023-01-12 JP JP2023003355A patent/JP2023037000A/ja active Pending
-
2024
- 2024-09-30 US US18/901,856 patent/US20250034271A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023037000A5 (https=) | ||
| JP2022101693A5 (https=) | ||
| JP2021527431A5 (https=) | ||
| JP2023089245A5 (https=) | ||
| JP2021501162A5 (https=) | ||
| HRP20201928T1 (hr) | Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1 | |
| JP2020502271A5 (https=) | ||
| JP2018532383A5 (https=) | ||
| RU2018126297A (ru) | Антитела, нацеленные на cd32b, и способы их применения | |
| JP2023505218A5 (https=) | ||
| JP2009521496A5 (https=) | ||
| JP2021520201A5 (https=) | ||
| JP2022525071A5 (https=) | ||
| JP2023549537A5 (https=) | ||
| JP2022512642A5 (https=) | ||
| JP2020528936A5 (https=) | ||
| JP2020515577A5 (https=) | ||
| JP2021525806A5 (https=) | ||
| JP2023509214A5 (https=) | ||
| JP2023543826A5 (https=) | ||
| JP2021520195A5 (https=) | ||
| JP2021533796A5 (https=) | ||
| JP2023545521A5 (https=) | ||
| JP2023516441A5 (https=) | ||
| JP2023547506A5 (https=) |